Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02203526
Title Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

diffuse large B-cell lymphoma

central nervous system lymphoma

Therapies

Dexamethasone + Etoposide + Ibrutinib + Pegylated liposomal-doxorubicin + Temozolomide

Cytarabine

Rituximab

Age Groups: adult
Covered Countries USA


No variant requirements are available.